Shionogi Pushes For Fast-Track Approval Of Flu Treatment Peramivir
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi announced Sept. 30 it is preparing to submit an application for approval for influenza treatment peramivir for A/H1N1 and other varieties of flu
You may also be interested in...
Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply
Shionogi announced Nov. 4 the company filed a new drug application for influenza drug peramivir with Japan's Ministry of Health, Labor and Welfare in October. The early NDA submission came just three month after the Osaka-based company completed a Phase III study for the drug
Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply
Shionogi announced Nov. 4 the company filed a new drug application for influenza drug peramivir with Japan's Ministry of Health, Labor and Welfare in October. The early NDA submission came just three month after the Osaka-based company completed a Phase III study for the drug
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo